KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2021)

Alnylam Pharmaceuticals' Non-Current Debt history spans 6 years, with the latest figure at $675.7 million for Q4 2021.

  • For Q4 2021, Non-Current Debt rose 253.25% year-over-year to $675.7 million; the TTM value through Dec 2021 reached $675.7 million, up 253.25%, while the annual FY2021 figure was $675.7 million, 253.25% up from the prior year.
  • Non-Current Debt reached $675.7 million in Q4 2021 per ALNY's latest filing, up from $191.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $675.7 million in Q4 2021 to a low of $30.0 million in Q4 2017.
  • Average Non-Current Debt over 5 years is $127.2 million, with a median of $30.0 million recorded in 2017.
  • Peak YoY movement for Non-Current Debt: tumbled 80.0% in 2018, then soared 253.25% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then soared by 537.59% to $191.3 million in 2020, then skyrocketed by 253.25% to $675.7 million in 2021.
  • Per Business Quant, the three most recent readings for ALNY's Non-Current Debt are $675.7 million (Q4 2021), $191.3 million (Q4 2020), and $30.0 million (Q2 2019).